4 August 2026

1QFY27 Results Update | Sector: Healthcare

Alembic Pharma

Estimate change	↔
TP change	↑
Rating change	↔

Bloomberg	ALPM IN
Equity Shares (m)	197
M.Cap.(INRb)/(USDb)	159.1 / 1.7
52-Week Range (INR)	1005 / 635
1, 6, 12 Rel. Per (%)	-3/6/-16
12M Avg Val (INR M)	113

Financials & Valuations (INR b)

Y/E MARCH	FY26	FY27E	FY28E
Sales	73.4	87.1	95.2
EBITDA	11.2	13.8	16.4
Adj. PAT	6.2	7.7	9.7
EBIT Margin (%)	10.9	11.4	12.8
Cons. Adj. EPS (INR)	31.7	39.0	49.6
EPS Gr. (%)	8.8	23.0	27.2
BV/Sh. (INR)	288.7	321.7	365.2
Ratios			
Net D:E	0.2	0.2	0.1
RoE (%)	11.5	12.8	14.4
RoCE (%)	12.2	11.5	12.9
Payout (%)	17.5	15.4	12.1
Valuations			
P/E (x)	25.6	20.8	16.3
EV/EBITDA (x)	18.1	14.7	12.1
Div. Yield (%)	0.6	0.6	0.6
FCF Yield (%)	3.2	3.1	4.3
EV/Sales (x)	2.7	2.3	2.1

Shareholding pattern (%)

As of	Jun-26	Mar-26	Jun-25
Promoter	69.9	69.7	69.7
DII	15.9	16.2	16.5
FII	4.2	4.3	4.0
Others	10.0	9.8	9.9

FII includes depository receipts

CMP: INR809 TP: INR845 (+4%) Neutral

Outperformance in the US drives an earnings beat in 1Q

Limited competition products improve the medium-term outlook

- Alembic Pharma (ALPM) delivered a better-than-expected financial performance with a 12%/19%/13% beat on revenue/EBITDA/PAT for 1QFY27. Strong growth in export formulations and the API segment resulted in a positive earnings surprise for the quarter.
- Specifically, the US sales, which were tracking an average quarterly run rate of USD55-60m for the past four years, surged to USD83m in 1QFY27, driven by limited competition product launches.
- The domestic formulation (DF) segment experienced a gradual uptrend in the specialty sub-segment. The animal health segment sustained its robust growth path in 1QFY27 as well.
- We broadly retain our estimates for FY27/FY28 as improved traction in the US segment (backed by product launches) and currency tailwinds are offset by higher depreciation and tax rates. We value ALPM at 17x 12M forward earnings to arrive at our TP of INR845.
- We expect the earnings growth momentum to strengthen over FY26-28, driving 25% earnings CAGR. This growth will be aided by product launches and scaling up of existing products in focus markets of the US and India. However, the current valuation provides limited upside, and hence we reiterate our **Neutral rating** on the stock.

Operating leverage partially offsets GM pressure

- ALPM's sales grew 25.7% YoY to INR21.5b (our est: INR 19.1b).
- Gross margin contracted 500bp YoY to 71.2%.
- However, EBITDA margin contracted at a lower rate of 100bp YoY to 15.4% due to better operating leverage (employee expenses/other expenses down 265bp/150bp as a % of sales).
- The R&D spending was INR1.9b (8.7% of sales).
- EBITDA grew 18% YoY to INR3.3b (our est: INR2.8b).
- Adj. PAT grew 12% YoY to INR1.7b. (our est: INR1.5b).

Export formulations & API growth offset weakness in the DF segment

- The US generics sales grew 49% YoY to INR7.8b (36% of sales).
- Ex-US generic export sales grew 17% YoY to INR3.8b (18% of sales).
- Domestic formulation (DF) sales grew 7% YoY to INR6.4b (30% of sales).
- API sales grew 33% YoY at INR3.5b (16% of sales).

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com) | **Eshita Jain - Research Analyst** (Eshita.Jain@MotilalOswal.com)
Vipul Mehta - Research Analyst (vipul.mehta@motilaloswal.com) | **Khyati Sonthalia - Research Analyst** (khyati.sonthalia@motilalOswal.com)

Key highlights from the management commentary

- On a constant-currency basis, US business grew ~37-38% YoY in 1QFY27. Excluding g-Bosutinib, the US revenue grew 20-25% YoY.
- ALPM raised its FY27 revenue growth guidance to a mid-to-high-teens rate for the US segment.
- ALPM now expects mid-teens YoY growth in revenue on an overall basis.
- ALPM reiterated an EBITDA margin dilution of ~150 bps for FY27.
- The US branded-specialty business is likely to reach breakeven by the end of FY27.
- The India human health business growth is expected to pick up over the next 1-2 quarters following the leadership change.
- Higher depreciation in 1QFY27 was largely attributable to the amortization of intangible assets acquired for the US branded business, with nearly 70-75% of the increase linked to such amortization.

Quarterly performance (INR m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			1Q	vs Est
Net Sales	**17,107**	**19,102**	**18,763**	**18,477**	**21,498**	**21,648**	**22,096**	**21,901**	**73,449**	**87,144**	**19,138**	**12%**
YoY Change (%)	9.5	15.9	10.8	4.4	25.7	13.3	17.8	18.5	10.1	18.6	11.9	
Total Expenditure	14,294	15,945	15,828	16,198	18,179	18,315	18,428	18,419	62,265	73,341	16,343	
EBITDA	**2,813**	**3,157**	**2,935**	**2,279**	**3,319**	**3,334**	**3,668**	**3,482**	**11,184**	**13,803**	**2,794**	**19%**
YoY Change (%)	18.8	31.9	12.8	-16.2	18.0	5.6	25.0	52.8	10.9	23.4	-0.7	
Margins (%)	16.4	16.5	15.6	12.3	15.4	15.4	16.6	15.9	15.2	15.8	14.6	
Depreciation	738	761	801	886	977	940	960	951	3,186	3,828	819	
EBIT	**2,075**	**2,396**	**2,134**	**1,393**	**2,342**	**2,394**	**2,708**	**2,531**	**7,999**	**9,974**	**1,975**	
YoY Change (%)	23.7	42.0	12.2	-31.3	12.8	-0.1	26.9	81.7	9.6	24.7	-4.8	
Interest	235	242	233	226	276	282	274	269	936	1,102	232	
Other Income	65	69	155	255	149	172	181	185	544	687	176	
PBT before EO expense	**1,905**	**2,223**	**2,056**	**1,423**	**2,215**	**2,284**	**2,615**	**2,446**	**7,607**	**9,559**	**1,920**	
Extra-Ord expense	0	0	422	248	0	0	0	0	-670	0	0	
PBT	**1,905**	**2,223**	**1,633**	**1,175**	**2,215**	**2,284**	**2,615**	**2,446**	**6,937**	**9,559**	**1,920**	
Tax	365	400	295	-829	495	466	510	453	231	1,923	384	
Rate (%)	19.1	18.0	18.1	-70.6	22.4	20.4	19.5	18.5	3.3	20.1	20.0	
MI & P/L of Asso. Cos.	-3	-24	8	-23	-11	0	0	0	-42	-11	0	
Reported PAT	**1,544**	**1,847**	**1,330**	**2,027**	**1,731**	**1,818**	**2,105**	**1,994**	**6,748**	**7,647**	**1,536**	
Adj PAT	**1,544**	**1,847**	**1,676**	**1,161**	**1,731**	**1,818**	**2,105**	**1,994**	**6,227**	**7,647**	**1,536**	**13%**
YoY Change (%)	14.6	29.7	21.1	-26.0	12.1	-1.6	25.6	71.7	8.8	22.8	-0.5	
Margins (%)	9.0	9.7	8.9	6.3	8.1	8.4	9.5	9.1	8.5	8.8	8.0	
EPS	**7.9**	**9.4**	**8.5**	**5.9**	**8.8**	**9.2**	**10.7**	**10.1**	**31.7**	**39.0**	**7.8**	

E: MOFSL Estimates

Key exhibits

Exhibit 1: DF sales grew 7.2% YoY in 1QFY27



Exhibit 2: International business grew 36.4% YoY in 1QFY27



Exhibit 3: Sales increased 25.7% YoY



Source: MOFSL, Company

Exhibit 4: EBITDA margin contracted 100bp YoY



Source: MOFSL, Company

Key highlights from the management commentary

- Expect API segment to grow 10% YoY for FY27.
- The US branded specialty business witnessed an encouraging initial response following the soft launch of Pivya, with physician feedback and product messaging remaining positive.
- The India business is expected to grow broadly in line with the IPM during FY27.
- Gross debt at ~INR16b. This is due to higher receivables arising from strong sales growth, with management expecting working capital normalization and debt reduction over the coming quarters

Exports to sustain growth traction; DF growth revival underway

US: Differentiated products to drive growth

- US formulation sales grew 49% YoY to INR7.8b in 1QFY27, driven primarily by volume expansion, new product launches and improved manufacturing utilization. Notably, the segment grew ~37-38% YoY in cc terms.
- Excluding Bosutinib, the US business grew ~20-25% YoY. Bosutinib contributed to one month of sales in Q1FY27 and shall benefit from 180-day exclusivity for the 100mg/500mg strengths until Nov-26.

- Alembic filed 4 ANDAs and received 10 approvals in 1QFY27, taking cumulative approvals to 279 with 185 products commercialized.
- ALPM expects to launch 15+ products in FY27.
- The soft launch of Pivya has seen an encouraging initial response, while the addition of Nuvessa further expands the company's specialty portfolio.
- Management remains focused on building a differentiated portfolio in complex generics and specialty products, which could support gradual improvements in US business over the medium term.
- We expect the US business to deliver a 23% sales CAGR over FY26-28 to INR33.5b, supported by new launches, specialty portfolio expansion and increasing contribution from differentiated products.

India: Human health segment gradually revives; animal health business remains resilient

- India branded business grew 7% YoY to INR6.4b in 1QFY27. The drag in performance was led by the acute/specialty segment, offset by the animal health business. Alembic retained its #21 rank in the Indian pharmaceutical market (IPM) with ~1.1% market share.
- Acute segment declined 2.1% YoY to INR1.3b while specialty/animal health segments grew 5.3%/24.1%YoY to INR3.7b/INR1.4b in 1QFY27.
- Acute therapies remained the key drag on the domestic business, although management highlighted improving traction in Azithral, cough & cold portfolio, indicating early signs of recovery.
- Specialty therapies continued to anchor the portfolio with 57% contribution, driven by gynecology, gastroenterology, ophthalmology and cardio-diabetes therapies.
- Prescription franchise remained healthy with prescriptions increasing to 137.6m in MAT Jun'26 (vs. 131.3m in MAT Jun'25), while its prescriber base expanded to 0.246m doctors.
- Execution remains a key focus, with the appointment of Mr Ramesh Juneja to drive productivity improvements, prescription quality and chronic portfolio expansion in the Human Health business.
- Animal health business remained resilient with 24% YoY growth to INR1.4b in 1QFY27 (22% CAGR over FY22-26). Management remains confident of sustaining 20%+ growth, supported by the poultry/farm animal portfolio and higher field-force productivity.
- With continued field-force expansion (5,800+ MRs), improving prescription coverage, chronic portfolio scale-up and strong momentum in animal health.
- We expect India branded business to deliver an 8% sales CAGR to INR28.5b over FY26-28.

Reiterate Neutral

- We broadly retain our estimates for FY27/FY28 as improved traction in the US segment (backed by product launches) and currency tailwinds are offset by higher depreciation and tax rates. We value ALPM at 17x 12M forward earnings to arrive at our TP of INR845.
- We expect the earnings growth momentum to strengthen over FY26-28, driving 25% earnings CAGR. This growth will be aided by product launches and scaling up of existing products in focus markets of the US and India. However, the current valuation provides limited upside, and hence we reiterate our **Neutral rating** on the stock.

Exhibit 5: P/E chart



Source: MOFSL, Company, Bloomberg

Exhibit 6: EV/EBITDA chart



Source: MOFSL, Company, Bloomberg

Story in charts

Exhibit 7: Formulation to post a 14% CAGR over FY26-28



Source: MOFSL, Company

Exhibit 8: Expect DF to post a 7.6% CAGR over FY26-28



Source: MOFSL, Company

Exhibit 9: EBITDA margin to expand 200bp over FY26-28



Source: MOFSL, Company

Exhibit 10: R&D expenses to remain around 7-8% of sales



Source: MOFSL, Company

Exhibit 11: EBITDA margin to expand with better operational efficiency



Source: MOFSL, Company

Exhibit 12: Earnings CAGR to remain at 25% over FY26-28



Source: MOFSL, Company

Financials and valuations

Consolidated - Income Statement (INRm)

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Net Sales	**53,058**	**56,530**	**62,280**	**66,721**	**73,449**	**87,144**	**95,200**
Change (%)	-1.6	6.5	10.2	7.1	10.1	18.6	9.2
EBITDA	**9,972**	**8,198**	**9,327**	**10,082**	**11,184**	**13,803**	**16,399**
Change (%)	-36.0	-17.8	13.8	8.1	10.9	23.4	18.8
Margin (%)	18.8	14.5	15.0	15.1	15.2	15.8	17.2
Depreciation	2,218	2,314	2,727	2,786	3,186	3,828	4,238
EBIT	**7,754**	**5,884**	**6,601**	**7,297**	**7,999**	**9,974**	**12,162**
Int. and Finance Charges	177	502	562	788	936	1,102	934
Other Income - Rec.	505	27	283	425	544	710	710
PBT bef. EO Exp.	**8,081**	**5,409**	**6,322**	**6,934**	**7,607**	**9,582**	**11,938**
EO Expense/(Income)	1,880	1,550	0	-129	670	0	0
PBT after EO Exp.	**6,201**	**3,859**	**6,322**	**7,063**	**6,937**	**9,582**	**11,938**
Current Tax	1,279	42	658	1,624	1,387	2,204	2,746
Deferred Tax	-235	84	-498	-373	-1,156	-281	-549
Tax Rate (%)	16.8	3.3	2.5	17.7	3.3	20.1	18.4
MI & P/L of Asso. Cos.	-300.3	309.2	-9.8	-22.9	-41.8	0.0	0.0
Reported PAT	**5,457**	**3,424**	**6,172**	**5,834**	**6,748**	**7,659**	**9,741**
PAT Adj for EO items	**6,889**	**4,296**	**6,172**	**5,723**	**6,227**	**7,659**	**9,741**
Change (%)	-41.5	-37.6	43.7	-7.3	8.8	23.0	27.2
Margin (%)	13.0	7.6	9.9	8.6	8.5	8.8	10.2

Consolidated - Balance Sheet (INRm)

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	393	393	393	393	393	393	393
Total Reserves	51,982	43,312	47,789	51,516	56,355	62,831	71,390
Preference Capital	0	0	0	0	0	0	0
Net Worth	**52,375**	**43,705**	**48,182**	**51,909**	**56,748**	**63,224**	**71,783**
Minority Interest	0	0	0	-14	-58	-58	-58
Deferred Liabilities	0	0	0	189	350	69	-480
Total Loans	7,021	7,051	4,933	12,423	14,299	14,201	14,103
Capital Employed	**59,397**	**50,756**	**53,115**	**64,508**	**71,339**	**77,437**	**85,348**
Gross Block	27,221	35,532	39,741	42,295	51,052	58,658	64,174
Less: Accum. Deprn.	9,234	11,548	14,274	17,060	20,246	24,074	28,312
Net Fixed Assets	**17,987**	**23,985**	**25,467**	**25,235**	**30,807**	**34,584**	**35,863**
Capital WIP	23,034	6,013	5,244	8,372	6,834	5,229	5,712
Total Investments	**1,184**	**963**	**930**	**1,272**	**1,409**	**1,409**	**1,409**
Curr. Assets, Loans&Adv.	**29,015**	**30,868**	**32,815**	**42,850**	**48,576**	**56,184**	**63,685**
Inventory	16,097	14,753	16,435	22,881	25,106	31,687	32,962
Account Receivables	8,071	10,464	10,248	13,998	14,663	16,951	18,258
Cash and Bank Balance	694	823	1,266	901	2,027	719	5,613
Loans and Advances	4,153	4,828	4,866	5,070	6,780	6,826	6,853
Curr. Liability & Prov.	**11,824**	**11,073**	**11,341**	**13,222**	**16,287**	**19,968**	**21,321**
Account Payables	7,064	6,798	7,356	8,799	8,351	11,832	12,468
Other Current Liabilities	3,165	2,512	2,237	2,321	5,295	6,282	6,863
Provisions	1,595	1,763	1,748	2,102	2,641	1,854	1,990
Net Current Assets	**17,192**	**19,795**	**21,474**	**29,628**	**32,289**	**36,215**	**42,364**
Appl. of Funds	**59,397**	**50,756**	**53,115**	**64,508**	**71,339**	**77,436**	**85,348**

Financials and valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Basic (INR)							
EPS	**35.0**	**21.9**	**31.4**	**29.1**	**31.7**	**39.0**	**49.6**
Cash EPS	46.3	33.6	45.3	43.3	47.9	58.4	71.1
BV/Share	266.5	222.4	245.1	264.1	288.7	321.7	365.2
DPS	10.4	4.2	5.2	5.2	5.2	5.2	5.2
Payout (%)	43.4	27.6	19.2	20.3	17.5	15.4	12.1
Valuation (x)							
P/E	23.1	37.1	25.8	27.8	25.6	20.8	16.3
Cash P/E	17.5	24.1	17.9	18.7	16.9	13.9	11.4
P/BV	3.0	3.6	3.3	3.1	2.8	2.5	2.2
EV/Sales	3.7	3.5	3.1	3.0	2.7	2.3	2.1
EV/EBITDA	19.7	23.9	20.7	20.0	18.1	14.7	12.1
Dividend Yield (%)	1.3	0.5	0.6	0.6	0.6	0.6	0.6
Return Ratios (%)							
RoE	13.9	8.3	13.5	11.5	11.5	12.8	14.4
RoCE	12.1	10.4	12.9	10.8	12.2	11.5	12.9
RoIC	20.6	14.7	14.5	12.1	13.4	12.2	13.9
Working Capital Ratios							
Asset Turnover (x)	0.9	1.1	1.2	1.0	1.0	1.1	1.1
Inventory (Days)	111	95	96	125	125	133	126
Debtor (Days)	56	68	60	77	73	71	70
Creditor (Days)	49	44	43	48	41	50	48
Leverage Ratio (x)							
Net Debt/Equity	0.1	0.1	0.1	0.2	0.2	0.2	0.1

Consolidated - Cash Flow Statement (INRm)

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Net Profit / (Loss) Before Tax	6,201	3,546	6,318	7,072	6,940	9,582	11,938
Depreciation	2,868	2,754	2,727	2,786	3,186	3,828	4,238
Interest & Finance Charges	131	502	562	788	936	392	224
Direct Taxes Paid	1,234	607	199	714	1,037	2,204	2,746
(Inc)/Dec in WC	-3,673	-576	-957	-9,214	-2,568	-5,234	-1,255
CF from Operations	**4,292**	**5,619**	**8,452**	**718**	**7,456**	**6,365**	**12,398**
Others	1,231	1,620	-819	383	751	0	0
CF from Operating incl EO	**5,524**	**7,239**	**7,633**	**1,101**	**8,207**	**6,365**	**12,398**
(inc)/dec in FA	-4,243	-4,434	-3,159	-5,539	-4,927	-6,000	-6,000
Free Cash Flow	**1,281**	**2,805**	**4,474**	**-4,437**	**3,280**	**365**	**6,398**
(Pur)/Sale of Investments	523	-64	-63	55	7	0	0
Others	17	22	32	-146	-134	710	710
CF from Investments	**-3,702**	**-4,476**	**-3,190**	**-5,629**	**-5,054**	**-5,290**	**-5,290**
Issue of Shares	0	0	0	0	0	0	0
(Inc)/Dec in Debt	1,300	-172	-2,312	7,385	1,406	-98	-98
Interest Paid	-519	-497	-494	-786	-881	-1,102	-934
Dividend Paid	-2,752	-1,966	-1,573	-2,162	-2,162	-1,183	-1,183
CF from Fin. Activity	**-2,186**	**-2,635**	**-4,379**	**4,437**	**-1,638**	**-2,383**	**-2,215**
Inc/Dec of Cash	**-364**	**129**	**64**	**-91**	**1,516**	**-1,308**	**4,894**
Add: Beginning Balance	1,059	694	823	1,266	901	2,027	719
Closing Balance	**694**	**823**	**887**	**1,175**	**2,416**	**719**	**5,612**
Total Cash and Cash Eq	**694**	**823**	**1,266**	**901**	**2,027**	**719**	**5,612**

Explanation of Investment Rating	
Investment Rating	**Expected return (over 12-month)**
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at
http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at
https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore.This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani
Email: nainesh.rajani@motilaloswal.com
Contact: (+65) 8328 0276
.

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
   MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
   Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
   MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
   MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
   MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

****

The associates of MOFSL may have:

financial interest in the subject company
actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
received compensation/other benefits from the subject company in the past 12 months
any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
Served subject company as its clients during twelve months preceding the date of distribution of the research report.
The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.
This report is meant for the clients of Motilal Oswal only.
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.
Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.
Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.
Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.